Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Ann Rheum Dis. 2024 Sep 30;83(10):1335-1344. doi: 10.1136/ard-2023-225415.
Vasculopathy emerges early in systemic sclerosis (SSc) and links to endothelial cell (EC) injury and angiogenesis. Understanding EC transcriptomes and epigenomes is crucial for unravelling the mechanisms involved.
Transcriptomes and chromatin accessibility were assessed by single-cell RNA sequencing and single-nucleus transposase-accessible chromatin sequencing. Immunofluorescent staining of skin and proteomics assay were employed to confirm the altered SSc EC phenotypes. Gain-of-function assay was used to evaluate the effects of ETS transcription factors on human dermal ECs (hDECs).
Both control and SSc ECs shared transcriptomic signatures of vascular linages (arterial, capillary and venous ECs) and lymphatic ECs. Arterial ECs in SSc showed reduced number and increased expression of genes associated with apoptosis. Two distinct EC subpopulations, tip and proliferating ECs, were markedly upregulated in SSc, indicating enhanced proangiogenic and proliferative activities. Molecular features of aberrant SSc-ECs were associated with disease pathogenesis and clinical traits of SSc, such as skin fibrosis and digital ulcers. Ligand-receptor analysis demonstrated altered intercellular networks of SSc EC subpopulations with perivascular and immune cells. Furthermore, the integration of open chromatin profiles with transcriptomic analysis suggested an increased accessibility of regulatory elements for ETS family transcription factors in SSc ECs. Overexpression of ETS genes in hDECs suggested ELK4, ERF and ETS1 may orchestrate arterial apoptosis and dysregulated angiogenesis in SSc.
This study unveils transcriptional and chromatin alterations in driving endovascular dysregulation in SSc, proposing ELK4, ERF and ETS1 as novel targets in ECs for addressing vascular complications in the condition.
血管病变在系统性硬化症(SSc)中早期出现,并与内皮细胞(EC)损伤和血管生成有关。了解 EC 的转录组和表观基因组对于揭示相关机制至关重要。
通过单细胞 RNA 测序和单核转座酶可及染色质测序评估转录组和染色质可及性。采用皮肤免疫荧光染色和蛋白质组学检测来确认改变的 SSc EC 表型。采用过表达功能测定来评估 ETS 转录因子对人真皮 EC(hDEC)的影响。
对照和 SSc EC 均具有血管谱系(动脉、毛细血管和静脉 EC 以及淋巴 EC)的转录组特征。SSc 中的动脉 EC 数量减少,与凋亡相关的基因表达增加。SSc 中明显上调了两个不同的 EC 亚群,即尖端和增殖 EC,表明增强了促血管生成和增殖活性。异常 SSc-EC 的分子特征与 SSc 的发病机制和临床特征(如皮肤纤维化和指溃疡)相关。配体-受体分析表明 SSc EC 亚群与血管周围和免疫细胞的细胞间网络发生改变。此外,将开放染色质图谱与转录组分析相结合表明,SSc EC 中的 ETS 家族转录因子的调控元件可及性增加。在 hDEC 中过表达 ETS 基因表明,ELK4、ERF 和 ETS1 可能协调 SSc 中的动脉细胞凋亡和失调的血管生成。
本研究揭示了驱动 SSc 血管内失调的转录和染色质改变,提出 ELK4、ERF 和 ETS1 作为 EC 中的新靶点,用于解决该病症中的血管并发症。